Spontaneous multiple cervical artery dissections after alemtuzumab

Area of Science:

• Neuroimmunology
• Vascular Neurology
• Pharmacology

Background:

• Alemtuzumab is an immunosuppressive therapy used for relapsing-remitting multiple sclerosis.
• Cervical artery dissection is a rare but serious condition affecting blood flow to the brain.
• Understanding adverse events associated with novel therapies is crucial for patient safety.

Observation:

• A case of multiple cervical artery dissections occurred four days after the first course of alemtuzumab.
• The patient had relapsing-remitting multiple sclerosis.

Findings:

• A potential causal relationship between alemtuzumab and cervical artery dissections is discussed.
• Proposed mechanisms involve an inflammatory process secondary to cytokine release, leading to arterial changes.

Implications:

• This case highlights the importance of monitoring for unexpected serious adverse events following alemtuzumab administration.
• Further investigation into the drug's vascular effects is warranted.